Amgen, bone mineral density

Amgen defends obesity drug amid bone concerns
After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and has asked the journal to issue a correction and add in the finalized data.
Amgen dismisses bone density concerns related to its weight-loss drug
Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone mineral density, a day after data from an early-stage study dragged its stock 7% lower.
Amgen Says No Link Between MariTide And Changes In Bone Mineral Density
Wednesday said there is no association between administration of experimental weight loss drug MariTide and changes
Amgen stock falls as analysts mull over weight loss drug's bone density data
Analysts cited data from a phase one study showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone mineral density over 12 weeks.
Amgen rebounds after denying bone safety concerns linked to obesity drug
Amgen (NASDAQ:AMGN) shares spiked in the premarket on Wednesday after the company ruled out concerns over loss of bone mineral density linked to its obesity candidate MariTide, which led to a ~7% decline in its share price in the previous session.
Amgen MariTide bone mineral density loss data ‘leaked,’ says Cantor Fitzgerald
Cantor Fitzgerald tells investors that MariTide’s Phase 1 data includes “a big surprise” as the supplemental appendix file
Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide's Impact on Bone Density
Amgen addresses safety concerns for its weight loss drug MariTide after new data suggests a potential 4% reduction in bone ...
pharmaphorum22h
Amgen plays down safety concern with obesity candidate
Amgen has rebuffed claims made by an analyst suggesting that its obesity drug MariTide is associated with reductions in bone ...
What’s Happening With Amgen Stock?
In this photo illustration, Amgen logo is displayed on a smartphone with a S&P ... [+] index website background. (Photo ...
STAT2d
A scrap of data on Amgen’s obesity drug candidate wipes out $12 billion in market value
a tiny shred of data on Amgen’s lead obesity candidate — not yet verified — erased $12 billion in market value. The data, ...
BioPharma Dive23h
Amgen shares sink on obesity drug concerns; AstraZeneca to spend $3.5B on manufacturing
An analyst note raising questions about Amgen’s MariTide triggered a stock sell-off Tuesday. Elsewhere, Roche and Novartis ...
Amgen issues statement regarding MariTide Phase 1 data
Amgen (AMGN) issued the following statement on the MariTide Phase 1 data. “As previously stated, Amgen does not see an association ...
Amgen slips as Cantor cites safety concerns linked to obesity candidate
Amgen (AMGN) stock falls as Cantor Fitzgerald raises safety concerns over bone mineral density loss linked to obesity ...
Hosted on MSN1d
Amgen dismisses bone density concerns related to its new weight-loss drug
The company's stock slumped 7% on Tuesday after analysts at Cantor Fitzgerald said their review of early-stage data on ...